Solventum (NYSE:SOLV) Raised to Outperform at Mizuho

Solventum (NYSE:SOLV) was upgraded by research analysts at Mizuho from a “neutral” rating to an “outperform” rating in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The firm currently has a $100.00 price target on the stock, up from their prior price target of $85.00. Mizuho’s price target indicates a potential upside of 24.59% from the stock’s current price.

SOLV has been the subject of a number of other research reports. Zacks Research lowered shares of Solventum from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. Stifel Nicolaus lifted their target price on Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Wall Street Zen upgraded Solventum from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. Piper Sandler reiterated an “overweight” rating on shares of Solventum in a report on Wednesday, December 17th. Finally, UBS Group reissued a “neutral” rating on shares of Solventum in a report on Friday, November 21st. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $90.27.

Solventum Price Performance

Solventum stock opened at $80.26 on Tuesday. The business’s fifty day moving average is $81.48 and its two-hundred day moving average is $75.66. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.14 and a current ratio of 1.50. The firm has a market cap of $13.92 billion, a P/E ratio of 9.25, a P/E/G ratio of 7.22 and a beta of 0.34. Solventum has a 52 week low of $60.70 and a 52 week high of $88.20.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, November 6th. The company reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The firm had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.05 billion. During the same quarter in the prior year, the firm earned $1.64 EPS. The company’s revenue was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Equities research analysts forecast that Solventum will post 6.58 earnings per share for the current fiscal year.

Solventum declared that its board has initiated a stock buyback program on Thursday, November 20th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the company to purchase up to 7.5% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s management believes its shares are undervalued.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Hilltop National Bank increased its stake in Solventum by 71.3% in the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after purchasing an additional 129 shares in the last quarter. Measured Wealth Private Client Group LLC bought a new stake in shares of Solventum in the 3rd quarter valued at $25,000. Deseret Mutual Benefit Administrators increased its position in shares of Solventum by 78.7% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock valued at $27,000 after buying an additional 163 shares in the last quarter. CYBER HORNET ETFs LLC acquired a new stake in Solventum during the 2nd quarter worth $28,000. Finally, Barrett & Company Inc. lifted its holdings in Solventum by 206.2% during the second quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock worth $30,000 after acquiring an additional 268 shares in the last quarter.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.